Everything drug pricing and policy, every day
And Lilly’s health benefits plan will work with an upstart PBM
And Lilly expands its pharm-to-table offering, pledging to make Trulicity and Emgality available directly to patients
Plus: Mark Cuban is trolling CVS, and I’m here for it
And a model for bringing MFN prices to Medicaid hints at how those prices might be calculated
And Novo’s earnings report sheds light on the Medicare obesity market and the impact of IRA “negotiations”
And Pfizer suggests that its MFN deal will leave a mark: “We expect a dilutive impact to our 2026 financial outlook.”
Is it time for a $10 million gene therapy?
